Fingerprint
Dive into the research topics of 'ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial
Stephen T. Oh, Moshe Talpaz, Aaron T. Gerds, Vikas Gupta, Srdan Verstovsek, Ruben Mesa, Carole B. Miller, Candido E. Rivera, Angela G. Fleischman, Swati Goel, Mark L. Heaney, Casey O. Connell, Murat O. Arcasoy, Yafeng Zhang, Jun Kawashima, Tomas Ganz, Mark Kowalski, Carrie Baker Brachmann
Research output: Contribution to journal › Article › peer-review
73
Scopus
citations